Bone density screening intervals for osteoporosis: One size does not fit all

JAMA

Volumn 307, Issue 24, 2012, Pages 2591-2592

  Yu, Elaine W ^a   Finkelstein, Joel S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

BONE DENSITOMETRY; BONE DENSITY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG EFFECT; EVIDENCE BASED MEDICINE; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; RESCREENING; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; TREATMENT DURATION; WOMEN'S HEALTH;

EID: 84862871640     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.6977     Document Type: Short Survey

References (10)

1. King AB, Fiorentino DM. Medicare payment cuts for osteoporosis testing reduced use despite tests' benefit in reducing fractures. Health Aff (Millwood). 2011; 30(12):2362-2370.
2. US Preventive Services Task Force. Screening for osteoporosis: recommendation statement. Am Fam Physician. 2011;83(10):1197-1200.
3. National Osteoporosis Foundation. NOF Clinician's Guide to Prevention and Treatment of Osteoporosis. http://www.nof.org/professionals/clinical -guidelines. Accessed February 11, 2012.
4. Nguyen TV, Center JR, Eisman JA. Femoral neck bone loss predicts fracture risk independent of baseline BMD. J Bone Miner Res. 2005;20(7):1195-1201. (Pubitemid 40863807)
5. Hillier TA, Stone KL, Bauer DC, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med. 2007;167(2):155-160. (Pubitemid 46148062)
6. Gourlay ML, Fine JP, Preisser JS, et al Study of Osteoporotic Fractures Research Group. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366(3):225-233.
7. Wainwright SA, Marshall LM, Ensrud KE, et al Study of Osteoporotic Fractures Research Group. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005;90(5):2787-2793. (Pubitemid 40686325)
8. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. WHO Fracture Risk Assessment Tool. http://www .shef.ac.uk/FRAX/tool.jsp. Accessed April 16, 2012.
9. Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM; Fracture Intervention Trial Research Group. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc. 2005;80(3):343-349. (Pubitemid 40316296)
10. Siris ES, Simon JA, Barton IP, McClung MR, Grauer A. Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int. 2008; 19(5):681-686.